A critical appraisal of brown adipose tissue metabolism in humans

Q Medicine

Clinical Lipidology Pub Date : 2015-06-01 DOI:10.2217/clp.15.14

D. Blondin, Sébastien M. Labbé, É. Turcotte, F. Haman, D. Richard, A. Carpentier

引用次数: 24

Abstract

Abstract The presence of brown adipose tissue (BAT) in adult humans has been rediscovered through the clinical use of the radioactive glucose analog 18F-fluorodeoxyglucose with PET. This has led to numerous studies demonstrating cold exposure as the major physiological modulator of BAT activity. These reports also suggested that age, gender, BMI and the presence of diabetes are also important modulators of BAT volume and metabolic activity. Although 18F-fluorodeoxyglucose PET has provided important information on BAT glucose metabolism, other techniques are being developed and applied to assess other aspects of BAT metabolism. Here, we summarize the current understanding of the pathophysiological functions of BAT in humans and discuss some of the strengths and limitations of the current investigational techniques.

查看原文本刊更多论文

人类棕色脂肪组织代谢的关键评估

通过临床使用放射性葡萄糖类似物18f -氟脱氧葡萄糖PET重新发现了成人棕色脂肪组织(BAT)的存在。这导致许多研究表明，冷暴露是BAT活性的主要生理调节剂。这些报告还表明，年龄、性别、BMI和糖尿病的存在也是BAT体积和代谢活性的重要调节因子。尽管18f -氟脱氧葡萄糖PET提供了关于BAT葡萄糖代谢的重要信息，但正在开发和应用其他技术来评估BAT代谢的其他方面。在这里，我们总结了目前对人类BAT病理生理功能的理解，并讨论了当前研究技术的一些优势和局限性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lipidology 生物-生化与分子生物学

CiteScore

0.44

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.